The effect of turmeric (Curcuma longa) extract on the functionality of the solute carrier protein 22 A4 (SLC22A4) and interleukin-10 (IL-10) variants associated with inflammatory bowel disease

Nutrients

Volumn 6, Issue 10, 2014, Pages 4178-4190

  McCann, Mark J ^a,b,c   Johnston, Sarah ^a,b   Reilly, Kerri ^a,b   Men, Xuejing ^a,b,c,d   Burgess, Elaine J ^b,e   Perry, Nigel B ^b,e   Roy, Nicole C ^a,b,c,d  

^a AGRESEARCH GRASSLANDS   (New Zealand)

^b Nutrigenomics New Zealand   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d MASSEY UNIVERSITY   (New Zealand)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Curcumin; IL 10; Inflammatory bowel disease; Nutrigenomics; OCTN1; SLC22A4; Turmeric

Indexed keywords

BETAINE; CURCUMA LONGA EXTRACT; CURCUMIN; DIMETHYL SULFOXIDE; INTERLEUKIN 10; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 4; THIONEINE; UNCLASSIFIED DRUG; PLANT EXTRACT; SLC22A4 PROTEIN, HUMAN; TURMERIC EXTRACT;

ARTICLE; CELL CULTURE; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DISEASE SEVERITY; FRACTIONATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEK293 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE; LIQUID SCINTILLATION COUNTING; NUTRIGENOMICS; PROMOTER REGION; QUANTITATIVE ANALYSIS; SITE DIRECTED MUTAGENESIS; SOLVENT EXTRACTION; CHEMISTRY; CURCUMA; DIET THERAPY; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; IN VITRO STUDY; INFLAMMATION; METABOLISM;

CURCUMA LONGA;

CURCUMA; CURCUMIN; EPITHELIAL CELLS; HEK293 CELLS; HUMANS; IN VITRO TECHNIQUES; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; ORGANIC CATION TRANSPORT PROTEINS; PLANT EXTRACTS;

EID: 84908190368     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6104178     Document Type: Article

References (47)

1. Conrad, K.; Roggenbuck, D.; Laass, M.W. Diagnosis and classification of ulcerative colitis. Autoimmun. Rev. 2014, 13, 463-466.
2. Laass, M.W.; Roggenbuck, D.; Conrad, K. Diagnosis and classification of crohn's disease. Autoimmun. Rev. 2014, 13, 467-471.
3. Ferguson, L.R. Nutrigenetics, nutrigenomics and inflammatory bowel diseases. Expert Rev. Clin. Immunol. 2013, 9, 717-726.
4. Ferguson, L.R. Potential value of nutrigenomics in crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 260-270.
5. Gruber, L.; Lichti, P.; Rath, E.; Haller, D. Nutrigenomics and nutrigenetics in inflammatory bowel diseases. J. Clin. Gastroenterol. 2012, 46, 735-747.
6. Thompson, A.I.; Lees, C.W. Genetics of ulcerative colitis. Inflamm. Bowel Dis. 2011, 17, 831-848.
7. Vermeire, S. Towards a novel molecular classification of IBD. Dig. Dis. 2012, 30, 425-427.
8. Franke, A.; McGovern, D.P.; Barrett, J.C.; Wang, K.; Radford-Smith, G.L.; Ahmad, T.; Lees, C.W.; Balschun, T.; Lee, J.; Roberts, R.; et al. Genome-wide meta-analysis increases to 71 the number of confirmed crohn's disease susceptibility loci. Nat. Genet. 2010, 42, 1118-1125.
9. McGovern, D.P.; Gardet, A.; Torkvist, L.; Goyette, P.; Essers, J.; Taylor, K.D.; Neale, B.M.; Ong, R.T.; Lagace, C.; Li, C.; et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat. Genet. 2010, 42, 332-337.
10. Shehzad, A.; Rehman, G.; Lee, Y.S. Curcumin in inflammatory diseases. Biofactors 2013, 39, 69-77.
11. Shishodia, S. Molecular mechanisms of curcumin action: Gene expression. Biofactors 2013, 39, 37-55.
12. Esatbeyoglu, T.; Huebbe, P.; Ernst, I.M.; Chin, D.; Wagner, A.E.; Rimbach, G. Curcumin-From molecule to biological function. Angew. Chem. Int. Ed. Engl. 2012, 51, 5308-5332.
13. Sareen, R.; Jain, N.; Pandit, V. Curcumin: A boon to colonic diseases. Curr. Drug Targets 2013, 14, 1210-1218.
14. Baliga, M.S.; Joseph, N.; Venkataranganna, M.V.; Saxena, A.; Ponemone, V.; Fayad, R. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: Preclinical and clinical observations. Food Funct. 2012, 3, 1109-1117.
15. Motawi, T.K.; Rizk, S.M.; Shehata, A.H. Effects of curcumin and ginkgo biloba on matrix metalloproteinases gene expression and other biomarkers of inflammatory bowel disease. J. Physiol. Biochem. 2012, 68, 529-539.
16. Larmonier, C.B.; Midura-Kiela, M.T.; Ramalingam, R.; Laubitz, D.; Janikashvili, N.; Larmonier, N.; Ghishan, F.K.; Kiela, P.R. Modulation of neutrophil motility by curcumin: Implications for inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17, 503-515.
17. Xavier, R.J.; Podolsky, D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448, 427-434.
18. Grundemann, D.; Harlfinger, S.; Golz, S.; Geerts, A.; Lazar, A.; Berkels, R.; Jung, N.; Rubbert, A.; Schomig, E. Discovery of the ergothioneine transporter. Proc. Natl. Acad. Sci. USA 2005, 102, 5256-5261.
19. Girardin, M.; Dionne, S.; Goyette, P.; Rioux, J.; Bitton, A.; Elimrani, I.; Charlebois, P.; Qureshi, I.; Levy, E.; Seidman, E.G.; et al. Expression and functional analysis of intestinal organic cation/l-carnitine transporter (OCTN) in crohn's disease. J. Crohn's Colitis 2012, 6, 189-197.
20. Palmieri, O.; Latiano, A.; Scimeca, D.; Bossa, F.; Corritore, G.; Latiano, T.; Andriulli, A.; Annese, V. IL23R, ATG16L1, IRGM, OCTN1, and OCTN2 mRNA expression in inflamed and noninflamed mucosa of IBD patients. Inflamm. Bowel Dis. 2011, 17, 1832-1833.
21. Yamamoto-Furusho, J.K.; Mendivil-Rangel, E.J.; Villeda-Ramirez, M.A.; Fonseca-Camarillo, G.; Barreto-Zuniga, R. Gene expression of carnitine organic cation transporters 1 and 2 (OCTN) is downregulated in patients with ulcerative colitis. Inflamm. Bowel Dis. 2011, 17, 2205-2206.
22. Lin, Z.; Nelson, L.; Franke, A.; Poritz, L.; Li, T.Y.; Wu, R.; Wang, Y.; MacNeill, C.; Thomas, N.J.; Schreiber, S.; et al. OCTN1 variant L503F is associated with familial and sporadic inflammatory bowel disease. J. Crohn's Colitis 2010, 4, 132-138.
23. Taubert, D.; Grimberg, G.; Jung, N.; Rubbert, A.; Schomig, E. Functional role of the 503F variant of the organic cation transporter OCTN1 in crohn's disease. Gut 2005, 54, 1505-1506.
24. Taubert, D.; Jung, N.; Goeser, T.; Schomig, E. Increased ergothioneine tissue concentrations in carriers of the crohn's disease risk-associated 503F variant of the organic cation transporter OCTN1. Gut 2009, 58, 312-314.
25. Russell, R.K.; Drummond, H.E.; Nimmo, E.R.; Anderson, N.H.; Noble, C.L.; Wilson, D.C.; Gillett, P.M.; McGrogan, P.; Hassan, K.; Weaver, L.T.; et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 2006, 55, 1114-1123.
26. Peltekova, V.D.; Wintle, R.F.; Rubin, L.A.; Amos, C.I.; Huang, Q.; Gu, X.; Newman, B.; van Oene, M.; Cescon, D.; Greenberg, G.; et al. Functional variants of OCTN cation transporter genes are associated with crohn disease. Nat. Genet. 2004, 36, 471-475.
27. Sanchez-Munoz, F.; Dominguez-Lopez, A.; Yamamoto-Furusho, J.K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 2008, 14, 4280-4288.
28. Kotlarz, D.; Beier, R.; Murugan, D.; Diestelhorst, J.; Jensen, O.; Boztug, K.; Pfeifer, D.; Kreipe, H.; Pfister, E.D.; Baumann, U.; et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: Implications for diagnosis and therapy. Gastroenterology 2012, 143, 347-355.
29. Shah, N.; Kammermeier, J.; Elawad, M.; Glocker, E.O. Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr. Allergy Asthma Rep. 2012, 12, 373-379.
30. Begue, B.; Verdier, J.; Rieux-Laucat, F.; Goulet, O.; Morali, A.; Canioni, D.; Hugot, J.P.; Daussy, C.; Verkarre, V.; Pigneur, B.; et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am. J. Gastroenterol. 2011, 106, 1544-1555.
31. Sanchez, R.; Levy, E.; Costea, F.; Sinnett, D. IL-10 and TNF-α promoter haplotypes are associated with childhood crohn's disease location. World J. Gastroenterol. 2009, 15, 3776-3782.
32. Franke, A.; Balschun, T.; Karlsen, T.H.; Sventoraityte, J.; Nikolaus, S.; Mayr, G.; Domingues, F.S.; Albrecht, M.; Nothnagel, M.; Ellinghaus, D.; et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 2008, 40, 1319-1323.
33. Cantor, M.J.; Nickerson, P.; Bernstein, C.N. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am. J. Gastroenterol. 2005, 100, 1134-1142.
34. Balding, J.; Livingstone, W.J.; Conroy, J.; Mynett-Johnson, L.; Weir, D.G.; Mahmud, N.; Smith, O.P. Inflammatory bowel disease: The role of inflammatory cytokine gene polymorphisms. Mediat. Inflamm. 2004, 13, 181-187.
35. Li, M.C.; He, S.H. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol. 2004, 10, 620-625.
36. Aithal, G.P.; Craggs, A.; Day, C.P.; Welfare, M.; Daly, A.K.; Mansfield, J.C.; Hudson, M. Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Dig. Dis. Sci. 2001, 46, 1520-1525.
37. Gasche, C.; Bakos, S.; Dejaco, C.; Tillinger, W.; Zakeri, S.; Reinisch, W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J. Clin. Immunol. 2000, 20, 362-370.
38. Zhu, H.; Lei, X.; Liu, Q.; Wang, Y. Interleukin-10-1082A/G polymorphism and inflammatory bowel disease susceptibility: A meta-analysis based on 17,585 subjects. Cytokine 2013, 61, 146-153.
39. Van der Linde, K.; Boor, P.P.; Sandkuijl, L.A.; Meijssen, M.A.; Savelkoul, H.F.; Wilson, J.H.; de Rooij, F.W. A Gly15Arg mutation in the interleukin-10 gene reduces secretion of interleukin-10 in crohn disease. Scand. J. Gastroenterol. 2003, 38, 611-617.
40. Fushimi, T.; Okayama, H.; Seki, T.; Shimura, S.; Shirato, K. Dexamethasone suppressed gene expression and production of interleukin-10 by human peripheral blood mononuclear cells and monocytes. Int. Arch. Allergy Immunol. 1997, 112, 13-18.
41. Andre, C.M.; Greenwood, J.M.; Walker, E.G.; Rassam, M.; Sullivan, M.; Evers, D.; Perry, N.B.; Laing, W.A. Anti-inflammatory procyanidins and triterpenes in 109 apple varieties. J. Agric. Food Chem. 2012, 60, 10546-10554.
42. Nissen, E.; Pauli, G.; Vollenbroich, D. Wst-1 assay-A simple colorimetric method for virus titration. In Vitro Cell. Dev. Biol. Anim. 1997, 33, 28-29.
43. McCann, M.J.; Rowland, I.R.; Roy, N.C. Anti-proliferative effects of physiological concentrations of enterolactone in models of prostate tumourigenesis. Mol. Nutr. Food Res. 2013, 57, 212-224.
44. Hande, K.R. Etoposide: Four decades of development of a topoisomerase ii inhibitor. Eur. J. Cancer 1998, 34, 1514-1521.
45. Tayyem, R.F.; Heath, D.D.; Al-Delaimy, W.K.; Rock, C.L. Curcumin content of turmeric and curry powders. Nutr. Cancer 2006, 55, 126-131.
46. Thomas, P.; Smart, T.G. Hek293 cell line: A vehicle for the expression of recombinant proteins. J. Pharmacol. Toxicol. Methods 2005, 51, 187-200.
47. Gota, V.S.; Maru, G.B.; Soni, T.G.; Gandhi, T.R.; Kochar, N.; Agarwal, M.G. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem. 2010, 58, 2095-2099.